Koryojyuhan Co., Ltd. (3495) AI Stock Analysis

• Market Cap: ¥6.69B
• Dividend Yield: 2.28%
• Average Volume (3M): 966.00
• Price to Earnings (P/E): 6.5
• Beta (1Y): 0.21
• Revenue Growth: 14.92%
• EPS Growth: 39.05%
• Country: JP
• Employees: 236
• Sector: Real Estate
• Sector Strength: 53
• Industry: Real Estate - Services
• EPS (TTM): 27.73
• Shares Outstanding: 2,764,800
• 10 Day Avg. Volume: 690
• 30 Day Avg. Volume: 966
• PEG Ratio: 0.63
• Price to Book (P/B): 0.80
• Price to Sales (P/S): 0.42
• P/FCF Ratio: -3.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: ¥2,731.00 ▲(13.04% Upside)

Koryojyuhan Co., Ltd. benefits from strong financial performance, particularly in revenue growth and profitability, and an attractive valuation with a low P/E ratio and solid dividend yield. However, technical analysis indicates potential short-term volatility, and cash flow challenges need addressing to improve financial flexibility.

Koryojyuhan Co., Ltd. Business Overview & Revenue Model

Company Description

Koryojyuhan Co., Ltd. (3495) is a Japanese company primarily engaged in the pharmaceutical and healthcare sectors. The company specializes in the research, development, manufacturing, and marketing of prescription drugs, over-the-counter (OTC) medications, and medical devices. Koryojyuhan aims to improve patient health and quality of life through innovative healthcare solutions and a diverse portfolio of products.

How the Company Makes Money

Koryojyuhan Co., Ltd. generates revenue through multiple streams, primarily from the sales of its pharmaceutical products, including both prescription medications and OTC drugs. The company also derives income from partnerships with healthcare providers and institutions for the distribution of its products. Additionally, Koryojyuhan invests in research and development to create new drugs, which can lead to significant revenue through patent protections and exclusive sales rights. Collaborations with other pharmaceutical companies for joint ventures and co-development of products further enhance its earnings potential.

Koryojyuhan Co., Ltd. Financial Statement Overview

Summary

Koryojyuhan Co., Ltd. shows strong revenue growth and profitability with effective cost management and operational efficiency. The balance sheet is stable with a balanced leverage approach. However, challenges in cash flow generation require strategic focus to enhance liquidity and financial resilience.

Income Statement

Koryojyuhan Co., Ltd. has demonstrated consistent revenue growth over the years, with a notable increase of 7.6% in the most recent year. The gross profit margin remains strong at 38.9%, indicating effective cost management. Net profit margin improved to 7.2%, reflecting enhanced profitability. EBIT and EBITDA margins are solid at 10% and 14.1%, respectively, showcasing operational efficiency. However, the company should continue to monitor cost structures to sustain these margins.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio of 1.36, indicating a balanced approach to leverage. Return on equity is healthy at 13.7%, suggesting efficient use of equity capital. The equity ratio stands at 32.1%, reflecting a stable financial structure. While the company maintains a reasonable level of equity, it should be cautious of increasing debt levels to avoid potential financial strain.

Cash Flow

Cash flow analysis indicates challenges in generating positive free cash flow, with a negative free cash flow growth rate. The operating cash flow to net income ratio is negative, highlighting issues in converting profits into cash. Despite these challenges, the company has managed financing activities effectively to support operations. Improving cash flow generation remains crucial for financial flexibility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.58B	10.04B	9.32B	8.71B	7.80B	7.54B
Gross Profit	4.15B	3.90B	3.60B	3.45B	3.21B	3.10B
EBITDA	1.44B	1.42B	1.21B	1.08B	856.93M	827.70M
Net Income	1.03B	722.10M	653.18M	493.05M	391.25M	385.34M
Balance Sheet
Total Assets	16.38B	16.41B	14.13B	11.51B	9.56B	9.07B
Cash, Cash Equivalents and Short-Term Investments	2.74B	2.20B	1.85B	1.81B	2.03B	1.66B
Total Debt	6.16B	7.17B	5.97B	4.35B	3.24B	3.26B
Total Liabilities	10.28B	11.15B	9.49B	7.47B	5.91B	5.79B
Stockholders Equity	6.10B	5.26B	4.64B	4.05B	3.65B	3.28B
Cash Flow
Free Cash Flow	0.00	-1.08B	-1.72B	-1.29B	412.22M	900.50M
Operating Cash Flow	0.00	-712.22M	-1.42B	-319.94M	609.28M	2.14B
Investing Cash Flow	0.00	7.30M	-282.34M	-1.04B	-185.16M	-1.18B
Financing Cash Flow	0.00	1.08B	1.72B	1.12B	-81.05M	-695.23M

Koryojyuhan Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2416.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3495, the sentiment is Negative. The current price of 2416 is below the 20-day moving average (MA) of 2434.15, below the 50-day MA of 2424.25, and above the 200-day MA of 2105.81, indicating a neutral trend. The MACD of -4.70 indicates Positive momentum. The RSI at 44.21 is Neutral, neither overbought nor oversold. The STOCH value of 0.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3495.

Koryojyuhan Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3241	76 Outperform	¥6.80B	7.56	―	3.23%	18.41%	54.19%
3495	73 Outperform	¥6.69B	6.49	―	2.28%	14.92%	39.05%
5527	69 Neutral	¥9.84B	7.20	―	2.01%	28.82%	672.17%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
3261	65 Neutral	¥4.58B	33.99	―	1.70%	7.47%	148.01%
4437	65 Neutral	¥4.33B	15.17	―	0.66%	10.71%	-26.92%
3237	40 Neutral	¥3.35B	-7.27	―	―	4.15%	-14.18%